Erythromycin-resistant _C. coli_ has been also observed in the USA, where Wang et al. demonstrated that 27% of pig strains were resistant and Taylor & Courvalin demonstrated high-level erythromycin resistance in strains of _C. coli_. More recently, Payot et al. showed the presence of resistant organisms isolated from fattening pigs in France, where erythromycin resistance was described to be 55%, with all isolates examined being _C. coli_.

Few laboratories in the UK identify their isolates to species level and fewer still utilize any of the recognized typing schemes. The combined consequences of these is that there is scanty information about the frequency and distribution of strain types that cause human infection and where they are to be found in the food chain. Hence, it may be important for laboratories to consider speciating such erythromycin-resistant isolates, to help in epidemiological investigations to identify potential animal sources, where such isolates may have originated.

Further work is therefore required to help ascertain the origins of the erythromycin resistance in these campylobacters, and careful monitoring/surveillance is also important to help observe resistance trends, so that increasing trends in resistance do not begin to impact on current antibiotic policies.

**Acknowledgements**

This study was funded by the Research & Development Office, Department of Health & Public Safety, Northern Ireland [Infectious Disease—Recognised Research Group (RRG) 9.9].

**References**


**Correspondence**

Jean-Winoc Decousser1,2*, Imen Methlouthi1, Patrick Pina3 and Pierre Allouch1 on behalf of The ColBVH Study Group1

1Service d’Hygien e Hospitalière, Centre Hospitalier de Versailles André Mignot, 177 rue de Versailles, 78150 Le Chesnay;
2Equipe Opérationnelle d’Hygiène, Laboratoire de Biologie, Centre Hospitalier de Dourdan, 2 rue du Poteau, 91415 Dourdan; 3Service de Médecine B, Hôpital de Plaisir Grignon, 220 rue Mansart, 78375 Plaisir, France

Keywords: carbapenems, _Streptococcus pneumoniae_, France, bacteraemia

*Corresponding author. Tel: +33-1-6081-5892; Fax: +33-1-6081-5897; E-mail: Jean-Winoc.Decousser@wanadoo.fr

The Collège de Bactériologie-Virologie Hygiène des Hôpitaux (ColBVH) Study Group participants are listed in the Acknowledgements.

Sir, _Streptococcus pneumoniae_ is the most common cause of infections of the lower respiratory tract in adults and children. In Europe, France has the highest rates of penicillin and erythromycin resistance in pneumococci: in 2002, 53% and 58% of the strains were found to be non-susceptible to these antibiotics, respectively. In American guidelines (but not in French guidelines), ertapenem, a newly licensed parenteral carbapenem, constitutes an alternative to the usual parenteral β-lactams for inpatients with pneumococcal infection. The purpose of this national multicentre study was to report the _in vitro_ susceptibility to ertapenem and comparator compounds of _S. pneumoniae_ isolated from French adults suffering from bacteraemic pneumonia.

Between 2000 and 2003, 339 strains of _S. pneumoniae_ were collected by The ColBVH Study Group, a network of 105 non-teaching hospitals representative of general hospitals in France. These non-duplicated isolates were from blood cultures from hospitalized adults with pneumonia and were sent to a central laboratory (Service d’Hygiène, Centre Hospitalier de Versailles). The MICs of ertapenem, and penicillin G, amoxicillin, cefuroxime, cefotaxime, ceftriaxone, imipenem, erythromycin, ceftazidime, and cefepime were determined by the Etest method. 1:2 serial dilutions of ertapenem were made in BHI broth with 5% human serum, and the results were compared with those of penicillin G, amoxicillin, cefuroxime, cefotaxime, ceftriaxone, imipenem, erythromycin, ceftazidime, and cefepime. The resistance rate to erythromycin and penicillin G was 58% and 53%, respectively. The MICs of ertapenem were significantly lower than those of the other antibiotics, especially amoxicillin and cefuroxime. 100% of the isolates were susceptible to ertapenem. The results of this study show that ertapenem is a valid alternative to the parenteral β-lactams for patients with pneumococcal infection in France.

Ertapenem was licensed in France in 2004. This study was funded by the Research & Development Office, Department of Health & Public Safety, Northern Ireland [Infectious Disease—Recognised Research Group (RRG) 9.9].
Correspondence

Table 1. Activity of antibiotics against 339 isolates of Streptococcus pneumoniae

<table>
<thead>
<tr>
<th>Antimicrobial agents</th>
<th>MIC50 (mg/L)</th>
<th>MIC90 (mg/L)</th>
<th>Range of MICs (mg/L)</th>
<th>%S</th>
<th>%I</th>
<th>%R</th>
</tr>
</thead>
<tbody>
<tr>
<td>Penicillin</td>
<td>0.032</td>
<td>2</td>
<td>0.008–4</td>
<td>56.6</td>
<td>27.1</td>
<td>16.3</td>
</tr>
<tr>
<td>Amoxicillin</td>
<td>0.032</td>
<td>1</td>
<td>0.008–4</td>
<td>98.8</td>
<td>1.2</td>
<td>0</td>
</tr>
<tr>
<td>Cefuroxime</td>
<td>0.064</td>
<td>4</td>
<td>0.008–16</td>
<td>62.2</td>
<td>3.2</td>
<td>34.6</td>
</tr>
<tr>
<td>Cefotaxime</td>
<td>0.032</td>
<td>1</td>
<td>0.008–4</td>
<td>96.8</td>
<td>2.9</td>
<td>0.3</td>
</tr>
<tr>
<td>Ceftriaxone</td>
<td>0.016</td>
<td>0.25</td>
<td>0.008–1</td>
<td>100</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Ertapenem</td>
<td>0.008</td>
<td>0.125</td>
<td>0.008–0.125</td>
<td>100</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Erythromycin</td>
<td>0.25</td>
<td>512</td>
<td>0.064–512</td>
<td>55.5</td>
<td>0</td>
<td>44.5</td>
</tr>
<tr>
<td>Quinupristin/dalfopristin</td>
<td>0.25</td>
<td>1</td>
<td>0.25–1</td>
<td>100</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Linezolid</td>
<td>1</td>
<td>1</td>
<td>0.5–2</td>
<td>100</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Levofloxacin</td>
<td>1</td>
<td>2</td>
<td>0.25–8</td>
<td>99.4</td>
<td>0</td>
<td>0.6</td>
</tr>
<tr>
<td>Gatifloxacin</td>
<td>0.25</td>
<td>0.5</td>
<td>0.032–8</td>
<td>99.4</td>
<td>0</td>
<td>0.6</td>
</tr>
<tr>
<td>Moxifloxacin</td>
<td>0.125</td>
<td>0.25</td>
<td>0.016–4</td>
<td>99.4</td>
<td>0</td>
<td>0.6</td>
</tr>
</tbody>
</table>

quinupristin/dalfopristin, linezolid, levofloxacin, gatifloxacin and moxifloxacin, were determined using the agar dilution method in ambient air and interpreted according to NCCLS guidelines.1 S. pneumoniae ATCC 49619 was used as a control strain.

Among the 339 pneumococci tested, 92 (27.1%) and 55 (16.3%) were penicillin-intermediate and -resistant, respectively (Table 1). Ceftriaxone, ertapenem, imipenem, linezolid and quinupristin/dalfopristin were constantly active, although the MIC90 of the first three compounds increased with penicillin resistance: 1, 0.25 and 0.125 mg/L for penicillin-resistant strain versus 0.016, 0.025 and 0.008 mg/L for penicillin-susceptible strains, respectively. In terms of percentage of full susceptible strains, ranking of β-lactams was: ertapenem = imipenem = ceftriaxone > amoxicillin > cefotaxime > cefuroxime > penicillin. Unlike cefuroxime, the in vitro activity of amoxicillin or cefotaxime remained high even amongst high-level penicillin-resistant strains. The percentage of erythromycin-susceptible strains decreased dramatically amongst penicillin non-susceptible isolates (88.5%, 17.4% and 3.6% of penicillin-susceptible, penicillin-intermediate and high-level penicillin-resistant pneumococci, respectively). Fluoroquinolones with enhanced activity against S. pneumoniae showed high in vitro activity (99.4% of susceptible strains).

Owing to the widespread occurrence of multidrug-resistant clones of S. pneumoniae, broad-spectrum cephalosporins combined with a macrolide and respiratory fluoroquinolones are now recommended for antibiotic therapy of severe pneumococcal infections.2 Ertapenem, which showed high in vitro and clinical efficiency against the main respiratory pathogens, could constitute an alternative antibiotic therapy.2,3 In this study, we have presented data concerning the ertapenem susceptibility of French bacteraemic isolates of S. pneumoniae. In terms of MIC50, this new compound seems to be at least as effective as ceftriaxone, the main comparator for the therapy of severe community-acquired pneumonia. These findings confirm data from previous studies.4 Nevertheless, the lack of ertapenem-intermediate or -resistant strains contrasts with the 40% of resistant strains amongst penicillin-resistant isolates reported in a recent Italian study.4 This dramatic discrepancy could probably be explained by the phenotypic characteristics of the penicillin-resistant isolates described here, which remained susceptible to third-generation cephalosporins. Amoxicillin, which showed high in vitro activity against pneumococci, could not be used in the empirical antibiotic therapy of severe pneumonia as the antimicrobial spectrum of this compound does not include β-lactamase-positive Haemophilus influenzae and Moraxella catarrhalis strains, two important agents of respiratory tract infections.5 Although cefuroxime and erythromycin were theoretically both active against S. pneumoniae, these agents are not recommended for empirical use in patients with severe pneumococcal infections. To date, imipenem, linezolid and quinupristin/dalfopristin were considered as second-line agents for multiresistant nosocomial bacteria and were not indicated in the antibiotic therapy of severe community-acquired lower respiratory tract infections. So the choice of empirical therapy of severe inpatient pneumonia was limited to third-generation cephalosporins (combined with a macrolide) or to an antipneumococcal fluoroquinolone. Concerning this last antibiotic class, some concerns have been raised regarding (i) the capacity of the phenotypic methods to detect first step mutants in S. pneumoniae and (ii) the role of prior quinolone use as a risk factor for subsequent infection with methicillin-resistant Staphylococcus aureus or quinolone-resistant Gram-negative bacilli.6 In the same way, the use of third-generation cephalosporins selects extended-spectrum β-lactamase-producing Klebsiella species.5 This ‘collateral damage’ as named by Paterson1 should be avoided with the use of ertapenem which is not hydrolysed by this kind of enzyme. Other investigational or licensed drugs such as faropenem or ketolides should be studied as comparator agents. However, for the time being, no parenteral formulation of these antibiotics is available. In summary, this study underlines the potential significant contribution of ertapenem in the parenteral therapy of bacteraemic pneumococcal pneumonia in France.

Acknowledgements

We received no funding from any pharmaceutical manufacturers.

We thank the microbiologists who participated in The ColBHV Study Group: J. Akli (Blois), C. Alba-Sauviat (Chaumont), G. Aubert (Saint Etienne), Amirlaant (Vierzon), J. Assens (St Afrique), J. P. Aubry (Quimperle), P. Aucher (Saint Jean D’angely),
We describe a refractory case of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia treated with daptomycin plus a penicillin agent. A 64-year-old male with a history of end-stage renal disease on haemodialysis, diabetes and right lower extremity amputation presented to the emergency room with fevers of 2 days duration. On admission, his temperature was 38.5°C. Examination revealed a clean, dry right subclavian vascular catheter, a grade 8 Wound Healing Site, and an unhealed site of the right lower extremity amputation. His WBC count was 17,400 cells/mm³. 

**References**


*Journal of Antimicrobial Chemotherapy* doi:10.1093/jac/dkh554

Advance Access publication 28 January 2005

**In vivo synergy of daptomycin plus a penicillin agent for MRSA?**

Marc Scheetz¹*, Pavani Reddy², Michael Postelnick¹ and John Flaherty²

¹Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL; ²Division of Infectious Diseases, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

Keywords: methicillin-resistant *Staphylococcus aureus*, therapy, lipopeptide

*Corresponding author. Tel: +1-312-926-2546; Fax: +1-312-926-7956; E-mail: mscheetz@nmh.org

Sirs,

We describe a refractory case of methicillin-resistant *Staphylococcus aureus* (MRSA) bacteraemia treated with daptomycin plus a penicillin agent. A 64-year-old male with a history of end-stage renal disease on haemodialysis, diabetes and right leg osteomyelitis status post below the knee amputation presented to the emergency room with fevers of 2 days duration. On admission, his temperature was 38.5°C. Examination revealed a clean, dry right subclavian vascular catheter, a grade III/VI holosystolic murmur and a 6 cm grade II ulcer at the healed site of the right lower extremity amputation. His WBC count was 17,400 cells/mm³.